Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$4.81 USD
-0.16 (-3.22%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $4.82 +0.01 (0.21%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
EDIT 4.81 -0.16(-3.22%)
Will EDIT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EDIT
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Other News for EDIT
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Wall Street Analysts Are Neutral on Top Healthcare Picks
Unveiling 5 Analyst Insights On Editas Medicine
Analysts’ Top Healthcare Picks: Editas Medicine (EDIT), Neurocrine (NBIX)